Results 181 to 190 of about 8,268,208 (290)

Comparison of HPV Antibodies Measured Prior to Diagnosis of Anal, Cervical, Oropharyngeal, Penile and Vaginal Cancers in the HPV Cancer Cohort Consortium

International Journal of Cancer, EarlyView.
ABSTRACT Antibodies against HPV proteins can provide pre‐diagnostic information about cancer development. We described the prevalence of antibodies to proteins of oncogenic HPV types prior to diagnosis of HPV‐related cancers. We analysed pre‐diagnostic blood from 1700 participants with incident HPV‐related cancers (anal = 387, cervical = 274 ...
Justina Ucheojor Onwuka, Marie‐Pierre Nobels, Aimée R. Kreimer, Lea Schroeder, Aida Ferreiro‐Iglesias, Ilir Agalliu, Demetrius Albanes, Qiuyin Cai, Gypsyamber D'Souza, Neal D. Freedman, Graham G. Giles, Allan Hildesheim, Wen‐Yi Huang, Kristian Hveem, Hilde Langseth, Roger L. Milne, Eivind Ness‐Jensen, Nicolas F. Schlecht, Lesley F. Tinker, Giske Ursin, Kala Visvanathan, Sylvia Wassertheil‐Smoller, Stephanie J. Weinstein, Wei Zheng, Mari Nygard, Mattias Johansson, Tim Waterboer, Gary M. Clifford, Hilary A. Robbins   +28 more
wiley   +1 more source

Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy. [PDF]

Cancer
Lane BR, Lewicki P, Noyes SL, Labardee C, Meah S, Daignault-Newton S, Hafron J, Morgan TM, Radhakrishnan A, Dess RT, Montie J, Ghani KR, Ginsburg KB, Borza T.   +13 more
europepmc   +1 more source

MLH1 p.His112Arg Variant Is Associated With Increased Cancer Susceptibility

International Journal of Cancer, EarlyView.
ABSTRACT Lynch syndrome, a prevalent hereditary cancer predisposition, is frequently caused by pathogenic variants in the MutL homolog 1 (MLH1) mismatch repair gene. However, a significant proportion of MLH1 missense variants remain classified as variants of uncertain significance (VUS), creating clinical ambiguity.
Amal Elfatih, Issam Tout, Najwa Ahmad Doha, Tala Abu Arja, Idris Mohammed, Doua Abdelrhaman, Waseem Hasan, Chadi Saad, Hamdi Mbarek, Borbala Mifsud, Sahar Isa Da'as   +10 more
wiley   +1 more source

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.

JAMA Netw Open
Siavoshi M, Frochen S, Fakunle M, Wadhwa A, Green-Lott AY, Bailey AV, Kwan L, Haroldsen C, Effiong A, Rose BS, Rebbeck TR, Iyer HS, Garraway IP.   +12 more
europepmc   +1 more source

Real-World Early Prostate-Specific Antigen Response Comparison Among Patients with Metastatic Castration Sensitive Prostate Cancer Treated with Apalutamide or Abiraterone Acetate in the United States. [PDF]

J Health Econ Outcomes Res
Lowentritt B, Bilen MA, Burbage S, Patel C, Kinkead F, Rossi C, Wong G, Pilon D, Shore N.   +8 more
europepmc   +1 more source

Cancer in the Oldest‐Old in Super‐Aging Japan: Trends and Characteristics From National Registry Data

International Journal of Cancer, EarlyView.
ABSTRACT Globally, Japan has the largest proportion of individuals aged ≥ 85 years. However, epidemiological studies on cancer in this age group are limited. This study aimed to investigate cancer trends and characteristics among the oldest‐old adults (aged ≥ 85 years) in Japan, using population‐based national and prefectural cancer registry data on ...
Sayo Tanaka, Hirokazu Tanaka, Kota Katanoda   +2 more
wiley   +1 more source

Apalutamide-induced prostate-specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review). [PDF]

Mol Clin Oncol
N S, Mv C, Upadhyay A, Sonone P, Dharmadhikari S, Puppalwar G, Khandhedia C, Mane A, Mehta S.   +8 more
europepmc   +1 more source

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

International Journal of Cancer, EarlyView.
ABSTRACT Medication taken for other reasons than for the treatment of malignant disease, termed concomitant medication, is known to affect outcomes when used with immune checkpoint inhibitor therapy and other oncological drugs. However, no research in humans has addressed the relationship between concomitant medications and efficacy of oncolytic ...
Santeri A. Pakola, Tatiana V. Kudling, Nea Ojala, James H. A. Clubb, Victor Arias, Elise Jirovec, Mirte van der Heijden, Arianna Eleuteri, Lyna Haybout, Susanna Grönberg‐Vähä‐Koskela, Katriina Jalkanen, Tuomo Alanko, Matthew S. Block, Inge Marie Svane, Anna Kanerva, Otto Hemminki, Dafne C. A. Quixabeira, Claudia Kistler, Suvi Sorsa, Victor Cervera‐Carrascon, Akseli Hemminki   +20 more
wiley   +1 more source

Prostate Specific Antigen Ordering After Implementation of a Point-of-Care Reminder to Discuss Screening. [PDF]

J Am Board Fam Med
Fenton JJ, Tancredi DJ.
europepmc   +1 more source

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Research Progress and Precision Diagnosis‐Therapy Under the Integrated Neuro–Immune–Metabolic–Microbiota Axis Framework

iMetaMed, EarlyView.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is increasingly recognized as a systemic disorder rather than a purely local prostate disease. The diagram illustrates the transition from the traditional local prostate‐centered model to a multi‐axis systemic framework involving clinical heterogeneity, local prostatic inflammation, systemic ...
Kun Wang, Jinfei Liu, Qiangsheng Wang, Lei Fan, Ziang Li, Xuexin Yu, Yonghao Chen, Xiaofan Lu, Guiyi Liao, Jialin Meng, Yu Guan   +10 more
wiley   +1 more source